Showing 5191-5200 of 7125 results for "".
- Lycored: Study Shows Preventive Effects and Protective Potential of Astaxanthin on Collagen Damagehttps://practicaldermatology.com/news/lycored-study-shows-preventive-effects-and-protective-potential-of-astaxanthin-on-collagen-damage/2461706/A study recently found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health. The study,
- FDA Set to Review Ortho Derm's Triple Combo Acne Gelhttps://practicaldermatology.com/news/fda-set-to-review-ortho-derms-triple-combo-acne-gel/2461705/The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Ortho Dermatologics’ investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel. The Prescription Drug User Fee Act (PDUFA) action date is set for October 20, 2023, accordin
- Incyte Taps Dr. Pablo J. Cagnoni for New Leadership Rolehttps://practicaldermatology.com/news/incyte-taps-dr-pablo-j-cagnoni-for-new-leadership-role/2461704/Pablo J. Cagnoni, MD, is Incyte’s New President and Head of Research & Development, effective June 5, 2023. In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte’s R&D efforts across its portfolio of programs in oncology, hematol
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang
- AI In Action: Rubedo Life Sciences Introduces RLS-1496 as a Potential First-in-Class Derm Drughttps://practicaldermatology.com/news/ai-in-action-rubedo-life-sciences-introduces-rls-1496-as-a-potential-first-in-class-derm-drug/2461699/Rubedo Life Sciences has nominated RL
- Resilia Pharmaceuticals Announces Return to Market of Neosalus Cream and Neosalus Lotionhttps://practicaldermatology.com/news/resilia-pharmaceuticals-announces-return-to-market-of-neosalus-cream-and-neosalus-lotion/2461697/Resilia Pharmaceuticals, Inc.’s Neosalus Cream and Neosalus Lotion are back. These products had not been available due to supply chain disruptions that occurred as a result of the COVID-19 public health crisis. Both Neosalus Lotion and Neosalus Cream use paten
- Cytrellis Taps New CTOhttps://practicaldermatology.com/news/cytrellis-taps-new-cto/2461695/Dr. Shiv Sabesan is Cytrellis Biosystems’ Chief Technology Officer. In his new role, Dr. Sabesan will lead the company's strategy as it continues to advance its proprietary ellacor Micro-Coring technology and expand indications. The technology was
- U.S. FDA Grants Breakthrough Therapy Designation to Spevigo for the prevention of GPP Flareshttps://practicaldermatology.com/news/us-fda-grants-breakthrough-therapy-designation-to-spevigo-for-the-prevention-of-gpp-flares-1/2461694/The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) to Spevigo for the prevention of generalized pustular psoriasis (GPP) flares, Boehringer Ingelheim reports. This designation follows the Center for Drug Evaluation (CDE) of China National Medic
- Arctiva Eczema Cream Spells Relief for 91% of Patientshttps://practicaldermatology.com/news/study-arctiva-eczema-cream-spells-relief-for-91-of-patients/2461688/Fully 91% of participants reported improvement in eczema irritation using proprietary Arctiva Eczema Cream, a new study shows. Arctiva Eczema Cream features Hydrosurf glycolipid technology—a blend of fermented ingredients with origins from Antarctica. It is combined with 1% C
- Aquavit News: Company Files Investigational New Drug Application for Dermatoxhttps://practicaldermatology.com/news/aquavit-news-company-files-investigational-new-drug-application-for-dermatox/2461687/Aquavit has filed an Investigational New Drug Application with the U.S Food and Drug Administration (FDA) for Dermatox (aqubotulinumtoxinA), their intradermal injection of botulinum toxin. AqubotulinumtoxinA has already received regulatory approvals in Asia, Sou